Project Grant R36DA061317

Award Date 6/1/24
Completion Date 5/31/26
Dollars Obligated $209K
Federal Grant Program
93.279
Assistance Type
Project Grant
Place of Performance
Lexington, KY 40526, USA
Similar Awards
This $196,236 Project Grant award from the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279) supports an early career investigator conducting research to address disparities in the prescription and effectiveness of medications to treat opioid use disorder (OUD) during pregnancy. The study aims to: (1) evaluate associations of race and segregation with buprenorphine and methadone use and opioid overdose during pregnancy; (2) elucidate...
This Project Grant award from the National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), provides $385,000.00 to Loyola University of Chicago's Health Sciences Campus to conduct research on integrated treatment approaches for co-occurring opioid use disorder (OUD) and alcohol use disorder (AUD). The key objectives of this 3-year research project are to: 1) assess the effectiveness of integrated treatment regimens, including first-line...
This federal Project Grant award from the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279) will develop novel econometric research designs to integrate real-world evidence (RWE) into the analysis of inconclusive randomized controlled trials (RCTs) for opioid use disorder (OUD) treatments. The $2,542,500 award, effective September 1, 2024 through August 31, 2027, will be administered by the Weill Medical College of Cornell University. The...
This federal Project Grant award of $844,475, provided by the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279), aims to test a bundled intervention to increase treatment uptake for patients with opioid use disorder (OUD) after emergency department (ED) discharge. The project will enroll 30 patients with OUD and nonfatal opioid overdoses in the R61 phase to assess the feasibility and acceptability of the bundled intervention, which...
This $297,061 Project Grant awarded by the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279) will fund the development and testing of a telehealth approach to provide opioid use disorder (OUD) treatment in high-risk settings. The project, titled "RIGHT TOOLS, RIGHT TIME, RIGHT PLACE: TELEHEALTH FOR OPIOID USE DISORDER IN VULNERABLE SETTINGS", aims to increase access to buprenorphine treatment for OUD in settings such as...
This $197,748 Project Grant award from the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279) aims to develop and pilot an enhanced low-dose buprenorphine initiation (LDI) program to improve treatment outcomes for individuals with opioid use disorder (OUD), particularly those using fentanyl. The key objectives are to: 1) identify barriers to LDI completion through patient, clinician, and system leader interviews; 2) design an enhanced LDI...
This $189,500 Project Grant award from the National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), aims to determine the extent to which cardiovascular disease (CVD) affects individuals with opioid use disorder (OUD) and how patients, providers, and payers can prevent CVD in this population. The 5-year award will utilize Medicaid data from 2016-2024 to examine the relationship between OUD and major adverse cardiovascular events, as well as the...
This federal Project Grant award, provided by the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279), supports a research project titled "The Cascade of Care for Patients with Opioid Use Disorder Identified Through a Large Public Health System." The $459,045 award, with an initial period of performance from September 30, 2024 to September 29, 2026, aims to modify the opioid use disorder (OUD) cascade of care model to better...
This Project Grant award from the National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), will support a randomized clinical trial to evaluate the effectiveness of targeted cognitive skills training interventions for offenders with substance use disorders. The $3,226,170 award, spanning September 2024 through May 2029, will be used by the Lovelace Biomedical Research Institute to conduct the trial. The research aims to validate prior findings...
This Project Grant award, valued at $177,170, was provided by the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279). The purpose of the grant is to analyze the implementation of Medications for Opioid Use Disorder (MOUD) in Massachusetts jails through a mixed-methods approach. The key products and services to be delivered include: Qualitative assessment of organizational factors related to MOUD implementation in jails and post-release...

EXAMINING THE IMPACT OF THE CRIMINAL LEGAL SYSTEM ON OPIOID USE DISORDER TREATMENT AND RECOVERY: A SOCIOECOLOGICAL PERSPECTIVE - THE PROPOSED R36 DISSERTATION PROJECT WILL ADVANCE SCIENTIFIC UNDERSTANDING OF THE CRIMINAL LEGAL SYSTEM'S (CLS) INFLUENCE ON OPIOID USE DISORDER (OUD) TREATMENT AND RECOVERY. CLS INVOLVEMENT IS COMMON AMONG THOSE WITH OUD, AND FOR MANY, THE CLS FACILITATES ACCESS TO TREATMENT SERVICES, EITHER THROUGH PROVISION OF TREATMENT SERVICES DURING INCARCERATION OR CONNECTION TO CARE UPON RELEASE. THERE IS AN INHERENT ROLE CONTRADICTION PRESENT HERE; SINCE THE CLS ALSO IS TASKED WITH MAINTAINING PUBLIC SAFETY, THERE COULD BE UNINTENDED CONSEQUENCES ON A PERSON'S RECOVERY POST-RELEASE. THE PROPOSED MIXED-METHODS STUDY ALIGNS WITH THE NIDA SERVICES RESEARCH BRANCH PRIORITY TO BETTER UNDERSTAND THE IMPACT OF CLS INVOLVEMENT ON SUBSTANCE USE, SERVICE ENGAGEMENT, AND RECOVERY. THIS PROJECT USES A SOCIOECOLOGICAL FRAMEWORK TO ENHANCE UNDERSTANDING OF THE COMMUNITY, INTERPERSONAL, AND INDIVIDUAL-LEVEL INFLUENCE OF THE CLS ON OUD TREATMENT AND RECOVERY. AIM 1 EXAMINES THE IMPACT OF THE CLS ON THE LANGUAGE USED TO DISCUSS OUD TREATMENT AND RECOVERY AMONG PEOPLE RESIDING AND WORKING IN COMMUNITIES HIGHLY IMPACTED BY THE OPIOID EPIDEMIC (COMMUNITY). THIS IS ACHIEVED VIA QUALITATIVE THEMATIC ANALYSIS OF PHOTOVOICE GROUP TRANSCRIPTS (N = 45 PARTICIPANTS) FROM THE KENTUCKY HEALING COMMUNITIES STUDY PHOTOVOICE PROTOCOL. AIM 2 ANALYZES THE EFFECT OF SOCIAL NETWORK CHANGES DURING REENTRY ON RETURN TO USE AT 6 MONTHS POST-RELEASE (INTERPERSONAL). AIM 2 IS ACHIEVED BY CONDUCTING SECONDARY DATA ANALYSIS USING DATA FROM THE GEOGRAPHIC VARIATION IN ADDICTION TREATMENT ENVIRONMENT (GATE) STUDY, A LONGITUDINAL COHORT STUDY EXAMINING MEDICATION USE FOR OUD TREATMENT AND OTHER RECOVERY OUTCOMES OF INDIVIDUALS WHO PARTICIPATED IN SUBSTANCE USE DISORDER TREATMENT PROGRAMMING WHILE INCARCERATED (N = 250). THE SECONDARY ANALYSES FOR AIM 2 USES LOGISTIC REGRESSION TO ANALYZE THE SOCIAL NETWORK PREDICTORS OF RETURN TO OPIOID AND OTHER SUBSTANCE USE. FINALLY, AIM 3 EVALUATES THE CLS-RELATED PREDICTORS OF INDIVIDUALS' PARTICIPATION IN MUTUAL AID SUPPORT GROUPS (E.G., ALCOHOLIC ANONYMOUS OR NARCOTICS ANONYMOUS) POST-RELEASE (INDIVIDUAL). USING THE GATE STUDY DATA, NEGATIVE BINOMIAL LOGISTIC REGRESSION ANALYZES THE EFFECT OF CLS-RELATED FACTORS ON THE NUMBER OF MUTUAL SUPPORT GROUPS ATTENDED IN THE 6-MONTHS AFTER RELEASE. RESULTS OF THIS PROJECT HIGHLIGHT THE URGENT NEED TO ADDRESS THE MULTI-LEVEL IMPACT OF THE CLS ON OUD TREATMENT AND RECOVERY IN ORDER TO COMBAT THE OPIOID EPIDEMIC AMONG PEOPLE INVOLVED WITH THE CLS. THE R36 AIMS WILL SERVE AS THE APPLICANT'S DISSERTATION. BECAUSE OUD RECOVERY IS NOT MERELY AN INDIVIDUAL PROCESS, BARRIERS TO RECOVERY MUST BE ADDRESSED AT ALL LEVELS OF CRIMINAL LEGAL SYSTEM INTERACTION TO BEST EFFECT CHANGE AND HAVE A SUSTAINED PUBLIC HEALTH IMPACT. THE R36 DISSERTATION PROJECT OUTLINED IN THIS APPLICATION LAUNCHES THE PRINCIPAL INVESTIGATOR ON A PATH TOWARDS BECOMING AN NIH INDEPENDENT INVESTIGATOR.

Posted 5/20/24, 12:00 AM